Plasma metabolite profiles identify pediatric medulloblastoma and other brain cancer

Shi, Zheng‐yuan; Yang, Chenlu; Xu, Xi‐qiao; Wu, Wanshui; Jiang, Dechun; Yan, Dan

doi:10.1007/s00216-022-04427-3

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, larkin et al, 126 recently showed metabolomic biomarkers in blood samples can be used to identify cancer with nonspecific symptoms 126 . A similar study by shi et al, identified 61 differential metabolites in the plasma of children with medulloblastoma 127 . Another study by Oshashi et al, 128 showed through metabolic profiling, metabolite levels differ between head and neck squamous cell carcinoma (HNSCC) and normal tissues 128 .…”

Section: Metabolite‐based Biomarkers For Diagnosis Prognosis and Pers...mentioning

confidence: 99%

“… 126 A similar study by shi et al, identified 61 differential metabolites in the plasma of children with medulloblastoma. 127 Another study by Oshashi et al, 128 showed through metabolic profiling, metabolite levels differ between head and neck squamous cell carcinoma (HNSCC) and normal tissues. 128 Such metabolite insights can significantly enhance diagnostic and prognostic outcomes in cancer patients.…”

Section: Metabolite‐based Biomarkers For Diagnosis Prognosis and Pers...mentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics in oncology

et al. 2023

View full text Add to dashboard Cite

Background: Oncogenic transformation alters intracellular metabolism and contributes to the growth of malignant cells. Metabolomics, or the study of small molecules, can reveal insight about cancer progression that other biomarker studies cannot.Number of metabolites involved in this process have been in spotlight for cancer detection, monitoring, and therapy.Recent Findings: In this review, the "Metabolomics" is defined in terms of current technology having both clinical and translational applications. Researchers have shown metabolomics can be used to discern metabolic indicators non-invasively using different analytical methods like positron emission tomography, magnetic resonance spectroscopic imaging etc. Metabolomic profiling is a powerful and technically feasible way to track changes in tumor metabolism and gauge treatment response across time. Recent studies have shown metabolomics can also predict individual metabolic changes in response to cancer treatment, measure medication efficacy, and monitor drug resistance. Its significance in cancer development and treatment is summarized in this review. Conclusion:Although in infancy, metabolomics can be used to identify treatment options and/or predict responsiveness to cancer treatments. Technical challenges like database management, cost and methodical knowhow still persist. Overcoming these challenges in near further can help in designing new treatment régimes with increased sensitivity and specificity.

show abstract

Section: Metabolite‐based Biomarkers For Diagnosis Prognosis and Pers...mentioning

confidence: 99%

Section: Metabolite‐based Biomarkers For Diagnosis Prognosis and Pers...mentioning

confidence: 99%

Metabolomics in oncology

et al. 2023

View full text Add to dashboard Cite

show abstract

Targeted metabolomic analysis of serum amino acids in heart failure patients

Yang,

Shi,

Bao

et al. 2024

Amino Acids

View full text Add to dashboard Cite

Heart failure (HF) has been recognized as a global epidemic with high rates of morbidity, hospitalization, and mortality. The role of amino acids, which provide the body with energy, in the development of HF is still unclear. The aim of this study was to explore changes in serum amino acids in patients with HF and identify potential biomarkers. First, the serum amino acid metabolism profiles of 44 patients with HF and 30 healthy controls (Con) were quantitatively measured. Then, candidate markers were identified through the utilization of T test, multivariate statistical analysis, and receiver operating characteristic (ROC) curve analysis. The results found that there were 11 amino acid levels that were significantly different between patients with HF and Con. Based on ROC curve analysis, the biomarkers of eight amino acids (Glutamic acid, Taurine, l-aspartic acid, l-ornithine, Ethanolamine, l-Serine, l-Sarcosine, and Cysteine) showed high sensitivity and specificity (AUC > 0.90), and binary logistic regression analysis was used in MetaboAnalyst 5.0. Among the amino acids examined, six exhibited notable alterations in accordance with the severity of HF. In conclusion, this study cannot only provide clinicians with an objective diagnostic approach for the early identification of HF, but also enhances comprehension of the underlying mechanisms involved in the pathogenesis of HF.

show abstract

Plasma metabolite profiles identify pediatric medulloblastoma and other brain cancer

Cited by 2 publications

References 34 publications

Metabolomics in oncology

Metabolomics in oncology

Targeted metabolomic analysis of serum amino acids in heart failure patients

Contact Info

Product

Resources

About